Sanofi (France)
NEWS
Sanofi’s experimental breast cancer treatment amcenestrant in combination with Pfizer’s Ibrance is showing promising anti-tumor activity in postmenopausal women with metastatic breast cancer.
It was another busy week for clinical trial announcement. Here’s a look.
Sanofi’s troubles stemming from the 2019 recall of Zantac appear to be far from over.
May is a busy month for the U.S. Food and Drug Administration (FDA)’s calendar for new drug reviews. Here’s a look.
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 27, 2021.
AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by RSV in healthy late preterm and term infants.
Sanofi will use its manufacturing capabilities to support the development of 200 million doses of the Moderna COVID-19 vaccine beginning in September.
JOBS
IN THE PRESS